Loading patent…
AssigneeAffyXell Therapeutics Co., Ltd.
InventorsKyong-Hoon Anh, Sung Hyun Choi, Kinam Kim, Jong Sang Ryu, Sengho Jeon
Estimating the term…
The present disclosure relates to a genetically modified stem cells (e.g., mesenchymal stromal cells (MSCs) or pluripotent stem cells (PSCs)) and populations thereof, that comprise an exogenous nucleic acid that encodes a binding protein that binds to a target. Targets include, for example, proteins expressed on activated immune cells. Binding proteins expressed by genetically modified stem cells as described herein can include one or more binding domains from an antibody or antibody mimetic. Also provided are methods of making genetically modified stem cells, pharmaceutical preparations including genetically modified stem cells, and methods of using the same, for example, in the treatment of immune diseases, including inflammatory, autoimmunity and cancer.
A population of genetically modified mesenchymal stromal cells (MSCs), wherein the MSCs comprise an exogenous nucleic acid comprising a coding sequence that encodes a binding agent that binds a target protein, wherein the binding agent comprises one or more binding domains from an antibody or antibody mimetic.
-5. (canceled)
(canceled)
(canceled)
-13. (canceled)
(canceled)
(canceled)
(canceled)
-27. (canceled)
-31. (canceled)
-37. (canceled)
A population of genetically modified pluripotent stem cells (PSCs), wherein the cells comprise an exogenous nucleic acid comprising a coding sequence that encodes a target binding agent, wherein the target binding agent comprises one or more binding domains from an antibody or antibody mimetic.
-52. (canceled)
(canceled)
-59. (canceled)
Dependencies are inferred from the claim text.